[Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].

Abstract

Blockade of the renin-angiotensin system with angiotensin-converting enzyme (ACE) inhibitors is now recognized as an effective approach for the treatment of hypertension and congestive heart failure. In addition, ACE inhibitors are very effective for the prevention of chronic renal failure. Today, it is possible to antagonize the effects of angiotensin II more specifically using AT1 receptor antagonists. Several non-peptide, orally active angiotensin II receptor antagonists have recently been developed clinically. These new molecules are as effective as ACE inhibitors, calcium antagonists and beta-blockers at reducing blood pressure in hypertensive patients. Furthermore, they appear to have similar systemic and renal hemodynamic properties in patients with congestive heart failure and renal diseases. Now, several large clinical trials such as the LIFE, the RENAAL and the ELITE II studies are under way to investigate the long-term benefits of one of these compounds in hypertension, heart failure and type II diabetic nephropathy.

• Authors: M Burnier, H R Brunner
• Journal: Therapie (Therapie) 1998 May-Jun Vol. 53 Issue 3 Pg. 279-84 ISSN: 0040-5957 [Print] France
• Vernacular Title: Antagonistes des récepteurs AT1 de l'angiotensine II: développement clinique et perspectives futures.
• PMID: 9773127 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Angiotensin II

Topics

• Angiotensin II (antagonists & inhibitors)
• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors (pharmacology, therapeutic use)
• Antihypertensive Agents (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Design
• Humans
• Hypertension (drug therapy)